An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: Gender-dependent effect

Acta Neurologica Scandinavica

Volumn 131, Issue 1, 2015, Pages 45-50

  Amiri Nikpour, M R ^a   Nazarbaghi, S ^a   Hamdi Holasou, M ^a   Rezaei, Y ^b  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ischemic stroke; Minocycline; National Institutes of Health Stroke Scale; Neuroprotection

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; MINOCYCLINE; NEUROPROTECTIVE AGENT;

AGED; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; STROKE; UNITED STATES;

AGED; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; NEUROPROTECTIVE AGENTS; PLATELET AGGREGATION INHIBITORS; SEX FACTORS; SINGLE-BLIND METHOD; STROKE; UNITED STATES;

EID: 84919971321     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12296     Document Type: Article

References (29)

1. Sacco RL, Kasner SE, Broderick JP et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 2013;44:2064-89.
2. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369:448-57.
3. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371:1612-23.
4. Zhu S, Stavrovskaya IG, Drozda M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8.
5. Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
6. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-308.
7. Du Y, Ma Z, Lin S et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 2001;98:14669-74.
8. Uz T, Pesold C, Longone P, Manev H. Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J 1998;12:439-49.
9. Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013;169:337-52.
10. Sonmez E, Kabatas S, Ozen O et al. Minocycline treatment inhibits lipid peroxidation, preserves spinal cord ultrastructure, and improves functional outcome after traumatic spinal cord injury in the rat. Spine (Phila Pa 1976) 2013;38:1253-9.
11. Tang XN, Wang Q, Koike MA et al. Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med 2007;48:1822-8.
12. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009;196:168-79.
13. Chu LS, Fang SH, Zhou Y et al. Minocycline inhibits 5-lipoxygenase expression and accelerates functional recovery in chronic phase of focal cerebral ischemia in rats. Life Sci 2010;86:170-7.
14. Li J, McCullough LD. Sex differences in minocycline-induced neuroprotection after experimental stroke. J Cereb Blood Flow Metab 2009;29:670-4.
15. Lampl Y, Boaz M, Gilad R et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007;69:1404-10.
16. Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term neuroprotection. Pharmacotherapy 2006;26:515-21.
17. Liu Z, Fan Y, Won SJ et al. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke 2007;38:146-52.
18. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998;95:15769-74.
19. Hoda MN, Li W, Ahmad A et al. Sex-independent neuroprotection with minocycline after experimental thromboembolic stroke. Exp Transl Stroke Med 2011;3:16.
20. Padma Srivastava MV, Bhasin A, Bhatia R et al. Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial. Neurol India 2012;60:23-8.
21. Kohler E, Prentice DA, Bates TR et al. Intravenous minocycline in acute stroke: a randomized. Controlled pilot study and meta-analysis. Stroke 2013;44:2493-9.
22. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 2005;25:502-12.
23. Yuan M, Siegel C, Zeng Z, Li J, Liu F, McCullough LD. Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp Neurol 2009;217:210-8.
24. Weng YC, Kriz J. Differential neuroprotective effects of a minocycline-based drug cocktail in transient and permanent focal cerebral ischemia. Exp Neurol 2007;204:433-42.
25. Fagan SC, Waller JL, Nichols FT et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke 2010;41:2283-7.
26. Matsukawa N, Yasuhara T, Hara K et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci 2009;10:126.
27. Li Y, Chopp M, Jiang N, Yao F, Zaloga C. Temporal profile of in situ DNA fragmentation after transient middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1995;15:389-97.
28. Beecher HK. The powerful placebo. J Am Med Assoc 1955;159:1602-6.
29. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602.